exon arrays

The company hopes to replicate its early data in future studies, making a case that better early diagnosis can improve outcomes for patients with schizophrenia and bipolar disorder.

In Genome Research this week: molecular autopsies for sudden death, telomere methylation in Arabidopsis, and more.

By Justin Petrone
Longtime array rivals Affymetrix and Illumina last week introduced new chips targeting the exome, exonic variants in the protein-coding regions of the human genome.

The researchers found that treatment with lactate and ketones causes cancer cells to express gene profiles associated with “stemness.” They believe that these gene signatures could, in turn, predict poor clinical outcome in breast cancer patients.

The new arrays, scheduled to launch later this month, will enable researchers to examine alternately expressed exons, and are in line with Agilent's effort to build its portfolio in the gene expression market.

The United Nations is to consider a ban on field testing gene drives at a meeting being held next week, Technology Review reports.

The Associated Press reports that gene-edited food may soon be for sale.

The US Department of Health and Human Services is beginning a series of meetings on human fetal tissue research, Stat News reports.

In Cell this week: epigenetic change linked to glioblastomas, rare and low-frequency variants contributing to multiple sclerosis risk, and more.